Literature DB >> 18254275

Phenotype analysis of tumour-infiltrating lymphocytes and lymphocytes in peripheral blood in patients with renal carcinoma.

Otakar Kopecký1, Sárka Lukesová, Vladimíra Vroblová, Doris Vokurková, Petr Morávek, Hynek Safránek, Dagmar Hlávková, Petr Soucek.   

Abstract

INTRODUCTION: When checking tumour growth, a number of observations indicate that the immune system plays a significant role in patients with renal cell carcinoma (RCC). Infiltration by lymphocytes (tumour infiltrating lymphocytes, TILs) is more prevalent in RCC than any other tumours. T lymphocytes are the dominant population of TIL cells. Views concerning the role of T lymphocytic subpopulations, B lymphocytes and NK cells in an anti-tumour response are not established. AIM: The aim is to determine the phenotype and activation of T and B lymphocytic subpopulations and NK cells and to compare their representation in tumour stroma and peripheral blood lymphocytes (PBL) in patients with RCC.
MATERIAL AND METHODS: Samples of peripheral blood taken from the cubital and renal veins and tumour stroma cells were obtained from 44 patients in the course of their surgeries carried out due to primary RCC. TILs were isolated from mechanically disintegrated tumour tissue. Immunophenotype multiparametric analysis of PBL and TILs was carried out. Their surface and activation characteristics were determined by means of flow cytometer.
RESULTS: CD3+ T lymphocytes (69.7%) were the main population of TILs. The number of CD3+/CD8+ T lymphocytes was significantly higher in TILs, 42.6% (p < 0.01), while CD4+ T lymphocytes were the majority population in peripheral blood, 41.35% (p < 0.001). The representation of CD3+/69+ T lymphocytes was significantly higher in TILs, 32.9%, compared to PBL (p < 0.001). On the contrary, the numbers of CD3+/CD25+, CD8+/57+ and CD4+/RA+ (naive CD4+ T lymphocytes) were higher in PBL (p < 0.001). The differences in representation of (CD3-/16+56+) NK cells and CD3+/DR+ T cells in TILs and PBL were not significant.
CONCLUSION: The above-mentioned results prove that the characteristics and intensity of anti-tumour responses are different in compared compartments (tumour/PBL). CD3+/CD8+ T lymphocytes are the dominant lymphocytic population of TILs. The knowledge of the phenotype and functions of effector cells, which are responsible for anti-tumour response, are the basic precondition for understanding the anti-tumour immune response and the cause of its failure.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 18254275

Source DB:  PubMed          Journal:  Acta Medica (Hradec Kralove)        ISSN: 1211-4286


  6 in total

Review 1.  Harnessing innate and adaptive immunity for adoptive cell therapy of renal cell carcinoma.

Authors:  Christiane Geiger; Elfriede Nössner; Bernhard Frankenberger; Christine S Falk; Heike Pohla; Dolores J Schendel
Journal:  J Mol Med (Berl)       Date:  2009-03-07       Impact factor: 4.599

Review 2.  Effects of obesity on immune responses to renal tumors.

Authors:  Vincent Chehval; Lyse A Norian
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

3.  Immunogenomic Analyses of the Prognostic Predictive Model for Patients With Renal Cancer.

Authors:  Tao Feng; Jiahui Zhao; Dechao Wei; Pengju Guo; Xiaobing Yang; Qiankun Li; Zhou Fang; Ziheng Wei; Mingchuan Li; Yongguang Jiang; Yong Luo
Journal:  Front Immunol       Date:  2021-10-12       Impact factor: 7.561

4.  Prognostic Value of Metabolism-Related Genes and Immune Infiltration in Clear Cell Renal Cell Carcinoma.

Authors:  Hanwen Li; Zengnan Mo
Journal:  Int J Gen Med       Date:  2021-10-18

5.  Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma.

Authors:  Michael T Serzan; Michael B Atkins
Journal:  J Cancer Metastasis Treat       Date:  2021-07-12

6.  Identification of an amino acid metabolism-associated gene signature predicting the prognosis and immune therapy response of clear cell renal cell carcinoma.

Authors:  Fan Zhang; Junyu Lin; Daiwen Zhu; Yongquan Tang; Yiping Lu; Zhihong Liu; Xianding Wang
Journal:  Front Oncol       Date:  2022-09-08       Impact factor: 5.738

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.